Lablabo creates pack for HRT treatment
Uses an airless metering dispenser with EasyFoil aluminium pouch
Lablabo’s pack consists of a Sillage airless metering dispenser with an EasyFoil aluminium pouch.
Made of an aluminium and polyethylen multilayer foil, this new pouch is said to ensure maximum protection of the product inside against oxygen and UV rays. Its cylindrical shape guarantees high restitution rates (up to 98% of the product delivered) and easy filling with basic equipment, the firm says.
The metering pump delivers a constant and precise dose of 0.92ml.
The Elestrin sales pack used by the Irish pharmaceutical firm includes two 38ml Sillage airless metering dispensers for a two-month treatment.
Lablabo, based in Annemasse, says it has Drug Master Files (DMFs) registered with the FDA for all of it products and received ISO 15378 certification last December.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Read moreHans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Sustainability
Redefining safety, efficiency, and sustainability: SCHOTT Pharma launches next generation polymer syringe system
A new cap design for prefillable polymer syringes provides tamper evidence at the individual syringe level, significantly reducing the risk of drug waste and ensuring patient safety. The integrated label concept, developed with Schreiner MediPharm, offers reliable first-opening indication, oxygen and light protection, and can include an RFID chip for accurate drug traceability and inventory management. A carton secondary packaging eliminates the need for blister packs, reducing waste and saving valuable storage space in hospitals and during transport, thereby cutting the carbon footprint of the entire value chain by up to 58%
Pharmaceutical
CellCarta and Leica Biosystems expand companion disgnostic development model partnership
Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation